Traditional implants in the gastrointestinal tract are meant to pass through a patient’s system, delivering a drug in short bursts or recording the health of a patient’s colon.
But in recent years, scientists have sought after ultra-long lasting ingestible devices that can deliver drugs for several weeks in a patient’s GI tract. Lyndra, Inc., a start-up based on such technology from the Massachusetts Institute of Technology, raised $23 million in April to support development of its star-shaped capsule.
Sustained-release drug delivery devices that reside in the gastrointestinal tract require a power source and, as gastroenterologist Giovanni Traverso told Drug Delivery Business News, batteries don’t make the cut.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.